Sygnature Discovery is a leading independent provider of integrated drug discovery resource and expertise. Our intellectual input and drug discovery expertise adds considerable value to clients’ research projects. The aim is to accelerate target validation, hit identification, hit-to-lead, lead optimisation and drug discovery programmes.
Sygnature’s capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, protein crystallography (via affiliate company Peak Proteins) and in vivo pharmacology (via RenaSci).
With a team of highly experienced and enthusiastic research scientists, we can collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.
In July 2018, the Sygnature Group acquired RenaSci. This enhanced the existing close working relationship and strategic partnership between Sygnature Discovery and RenaSci.
Sygnature Discovery and RenaSci share the same values: we both aim to provide high quality science with a strong customer focus. Our co-location at BioCity Nottingham enables a seamless integration of capabilities within drug discovery and pre-clinical development. Clients of each company can now access a wider range of technologies and services to enhance their drug R&D projects.
You can find out more about Sygnature Discovery at www.sygnaturediscovery.com
For more details or information on how we can support your project please complete the contact form.